Menu Search
Equities

Balchem Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BL9B:DUS

Balchem Corp

Actions
  • Price (EUR)146.60
  • Today's Change0.80 / 0.55%
  • Shares traded60.00
  • 1 Year change-6.86%
  • Beta0.9425
Data delayed at least 15 minutes, as of Feb 06 2026 18:31 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

  • Revenue in USD (TTM)1.01bn
  • Net income in USD149.20m
  • Incorporated1967
  • Employees1.36k
  • Location
    Balchem Corp5 Paragon DriveMONTVALE 07645United StatesUSA
  • Phone+1 (845) 326-5600
  • Fax+1 (845) 326-5742
  • Websitehttps://balchem.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.